antiviral news

Press Releases in the global landscape

Mar 2, 2026

Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M

Bioxytran reported positive Phase 1b/2a trial results for its antiviral candidate ProLectin-M in mild to moderate COVID-19, showing faster viral clearance and a favorable safety profile.

Feb 27, 2026

KDCA to halt use of unapproved Covid-19 drug Lagevrio as stock runs out

The Korea Disease Control and Prevention Agency announced it will suspend use of the COVID-19 drug Lagevrio (molnupiravir) due to depleted stock and incomplete product approval.

Feb 19, 2026

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

Completed clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were recapitulated in PAXLOVID®-ineligible patients, representing a significant population with no effective treatment options.

Feb 5, 2026

The Ministry of Health has approved nine home treatment regimens for COVID-19

Feb 1, 2026

The Ministry of Health approved permanent recommendations for the treatment of COVID-19

Among the drugs recommended for use in outpatient settings are molnupiravir, favipiravir, nirmatrelvir with ritonavir, as well as other active substances.

Jan 27, 2026

Chinese scientists identify oral drug VV116 as promising Nipah virus treatment

A new study by several Chinese research teams has found that the oral nucleoside drug VV116 possesses strong antiviral activity against the Nipah virus (NiV), offering fresh hope in the fight against this emerging highly lethal infectious disease, according to the Wuhan Institute of Virology, Chinese Academy of Sciences.